Sanofi, Beyfortus
Sanofi Beats Q3 Forecasts Fueled by 381% Growth in Beyfortus Sales
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.
Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.
Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.
Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...
Ottawa Public Health is recommending that eligible residents at higher risk of severe illness protect themselves against ...
Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback